Biomarin Pharmaceutical Inc
Change company Symbol lookup
Select an option...
BMRN Biomarin Pharmaceutical Inc
ADXRF Adx Energy Ltd
CPB Campbell Soup Co
BLTS Bright Lights Acquisition Corp
MMM 3M Co
STRR Star Equity Holdings Inc
BMY Bristol-Myers Squibb Co
BCTX Briacell Therapeutics Corp
ENV Envestnet Inc
CDR-B Cedar Realty Trust Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.

Closing Price
$80.97
Day's Change
2.11 (2.68%)
Bid
--
Ask
--
B/A Size
--
Day's High
81.20
Day's Low
78.65
Volume
(Light)
Volume:
659,473

10-day average volume:
952,848
659,473

BMRN's position in the Biotechnology industry

Industry PeersBMRNMRNAALNYSRPTIONS

Summary

Company ProfileBioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and...
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA...
Go to MRNA summary
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and...
Go to ALNY summary
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted...
Go to SRPT summary
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on our cardiovascular and neurology franchises. Its...
Go to IONS summary
52-Week Change

VS. INDUSTRY
4.67%
-17.76%
-8.89%
-2.88%
2.12%
Market Cap

VS. INDUSTRY
$15.0B
$58.7B
$15.4B
$6.5B
$5.3B
Beta

VS. INDUSTRY
0.4
1.7
0.9
1.3
0.8
Dividend Yield

VS. INDUSTRY
--
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
526.91x
4.34x
--
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$1.9B
$22.6B
$880.0M
$765.8M
$840.8M
Profit Margin

VS. INDUSTRY
1.88%
64.77%
-101.47%
-46.56%
-0.46%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
--
--
--
Revenue Growth (TTM)

VS. INDUSTRY
1.91%
727.23%
54.13%
33.56%
18.84%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.